[Complete remission after Rituximab treatment in refractory hairy cell leukemia].

Abstract

A 40 year-old man with hairy cell leukemia (HCL) was treated with Cladribin, but achieved only partial response (PR). As expected, both 2 and 5 years later the disease had progressed and the patient was therefore twice retreated with Cladribin. A bone marrow examination after the last Cladribin course showed complete response with residual disease (CR-RD). The patient received consolidation therapy with Rituximab, achieved complete response (CR) and was still in CR 9 months later. Rituximab is a good treatment option for patients with refractory HCL because of its significant activity and minimal toxicity.

• Authors: Irma Petruskevicius, Anne Bukh, Henrik Mertz, Hans Erik Johnsen
• Journal: Ugeskrift for laeger (Ugeskr Laeger) Vol. 170 Issue 26-32 Pg. 2350 (Jun 23 2008) ISSN: 1603-6824 [Electronic] Denmark
• Vernacular Title: Komplet remission efter rituximabbehandling ved refraktaer hårcelleleukaemi.
• PMID: 18570771 (Publication Type: Case Reports, English Abstract, Journal Article)

Chemical References

• Antibodies, Monoclonal
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents
• Rituximab

Topics

• Adult
• Antibodies, Monoclonal (therapeutic use)
• Antibodies, Monoclonal, Murine-Derived
• Antineoplastic Agents (therapeutic use)
• Humans
• Leukemia, Hairy Cell (drug therapy)
• Male
• Neoplasm Recurrence, Local
• Remission Induction
• Rituximab